Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?

Clinical Medicine Insights: Oncology - New Zealand
doi 10.4137/cmo.s6087
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

SAGE Publications

Related search

Rationale for Targeted Therapies and Potential Role of Pazopanib in Advanced Renal Cell Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2010English

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2019English

Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2018English

Real-World Clinical Outcomes of Pazopanib Immediately Following Immunotherapy Discontinuation for the Treatment of Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2020English

Angiogenesis Genotyping in the Selection of First-Line Treatment With Either Sunitinib or Pazopanib for Advanced Renal Cell Carcinoma

Oncotarget
Oncology
2016English

Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients With Advanced Renal Cell Carcinoma Treated With Pazopanib

Oncology
MedicineCancer ResearchOncology
2015English

New Advancements and Developments in Treatment of Renal Cell Carcinoma: Focus on Pazopanib

OncoTargets and Therapy
OncologyPharmacology
2010English

The Bevacizumab Experience in Advanced Renal Cell Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2010English

Management of Locally Advanced Renal Cell Carcinoma

Cancer Control
MedicineOncologyHematology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy